Year All202620252024202320222021 Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock 08-09-2024 Zevra Therapeutics Announces Proposed Public Offering of Common Stock 08-08-2024 Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference 08-07-2024 FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C 08-02-2024 Zevra Therapeutics to Report Second Quarter 2024 Financial Results 07-30-2024 Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C 07-09-2024 Zevra Therapeutics Expands Executive Leadership Team 06-25-2024 Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders 06-18-2024 Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting 06-03-2024 Zevra Therapeutics to Participate at Upcoming Investor Events 05-09-2024
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C 08-02-2024
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C 07-09-2024
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders 06-18-2024
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting 06-03-2024
